Join 250 fellow retina specialists for a unique educational experience in vitreoretinal medicine. This program is designed by and for retina specialists, offering updates on the most recent advances and their integration into everyday practice as well as insight into varying challenges, including the implementation of new diagnostic and treatment modalities. In a relaxed setting, faculty and attendees can discuss specific cases, new therapy and imaging techniques and the latest surgical strategies.
This program offers a non-concurrent schedule including: breakfast programs, general sessions, exhibit breaks, lunch programs and evening banyan tree sessions (all included in the single registration fee). Retina Program attendees are also able to attend sessions of interest under the Hawaiian Eye Comprehensive Ophthalmologist Program.
Upon completion of this activity, attendees should be better able to:
Explain the new developments in optical coherence tomography (OCT) technology, including angiography, swept source, wide-field, and en face, and the use of OCT in guiding treatment strategies.
Describe the current trends in the diagnosis and treatment of macular degeneration, including the management of neovascular AMD, macular hole, , use of specific dosing regimens, complement inhibition, gene therapy, and other novel treatments.
Explore new pathways for targeting treatment in retinal vascular diseases.
Examine the evidence on current and emerging treatment paradigms for diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).
Assess current clinical trials and emerging treatment approaches for retinal venous occlusion.
Review current trends in the management of pediatric retinal disorders.
Examine new trends in the management of neuro-ophthalmic disorders and ocular trauma.
Summarize new management concepts in vitreoretinal surgery, including the surgical delivery of therapies, management of uveitis, retinal detachment, vitreomacular traction, macular hole, and other vitreoretinopathies.
Describe current diagnostic modalities as well as management options for choroidal masses, melanoma, and other ocular tumors.
This continuing medical education activity is provided by
Retina 2019 is supported, in part, by independent educational grants from AbbVie, Inc.; Alcon Laboratories, Inc.; Alimera Sciences, Inc.; Allergan, Inc.; Bausch + Lomb; Carl Zeiss Meditec, Inc.; EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; Mallinckrodt Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Santen Inc.
ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 35.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INTERNATIONAL NOTICE: This educational activity is designated for AMA PRA Category 1 Credit(s)™ for all US physicians. US physicians will receive a CME certificate and non-US physicians should contact their respective organizations for reciprocity of credit.
FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.
NOTICE: Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.